0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <div class="section"> <a class="named-anchor" id="S1"> <!-- named anchor --> </a> <h5 class="section-title" id="d6447635e194">Study Objective</h5> <p id="P2">To explore the potential occurrence of long-term side effects and tolerability of gonadotropin-releasing hormone agonist (GnRHa) plus 2 different add-back regimens in adolescent patients with endometriosis </p> </div><div class="section"> <a class="named-anchor" id="S2"> <!-- named anchor --> </a> <h5 class="section-title" id="d6447635e199">Design</h5> <p id="P3">Follow-up questionnaire sent in 2016 to patients who participated in a drug trial between 2008–2012 </p> </div><div class="section"> <a class="named-anchor" id="S3"> <!-- named anchor --> </a> <h5 class="section-title" id="d6447635e204">Setting</h5> <p id="P4">Tertiary care center in Boston, MA.</p> </div><div class="section"> <a class="named-anchor" id="S4"> <!-- named anchor --> </a> <h5 class="section-title" id="d6447635e209">Participants</h5> <p id="P5">Females with surgically confirmed endometriosis (n=51) who enrolled in a GnRHa plus add-back trial as adolescents </p> </div><div class="section"> <a class="named-anchor" id="S5"> <!-- named anchor --> </a> <h5 class="section-title" id="d6447635e214">Interventions</h5> <p id="P6">Leuprolide depot 11.25 mg intramuscular injection every 3 month, plus oral norethindrone acetate 5 mg daily or oral norethindrone acetate 5 mg daily plus oral conjugated equine estrogens 0.625 mg daily. </p> </div><div class="section"> <a class="named-anchor" id="S6"> <!-- named anchor --> </a> <h5 class="section-title" id="d6447635e219">Main Outcome Measure(s)</h5> <p id="P7">Side effects during and after treatment, irreversible side effects, changes in pain, overall satisfaction </p> </div><div class="section"> <a class="named-anchor" id="S7"> <!-- named anchor --> </a> <h5 class="section-title" id="d6447635e224">Results</h5> <p id="P8">The response rate was 61%. Almost all (96%) reported side effects during treatment; 80% reported side effects lasting &gt; 6 months after stopping treatment. Almost half (45%) reported side effects they considered irreversible, including memory loss, insomnia, and hot flashes. Despite side effects, subjects rated GnRHa plus add-back as the most effective hormonal medication for treating endometriosis pain; two thirds (16/25) would recommend it to others. More subjects who received a modified two drug add-back regimen versus standard one drug add-back would recommend GnRHa and felt it was the most effective hormonal medication. </p> </div><div class="section"> <a class="named-anchor" id="S8"> <!-- named anchor --> </a> <h5 class="section-title" id="d6447635e229">Conclusion</h5> <p id="P9">Subjects felt GnRHa plus add-back was effective and would recommend it to others, despite significant side effects. Those who received two drug add-back reported more success than those who received standard add-back. A subset of patients reported irreversible side effects. </p> </div><div class="section"> <a class="named-anchor" id="S9"> <!-- named anchor --> </a> <h5 class="section-title" id="d6447635e234">Clinical Trial registration</h5> <p id="P10">ClinicalTrials.gov, NCT00474851</p> </div>

          Related collections

          Author and article information

          Journal
          Journal of Pediatric and Adolescent Gynecology
          Journal of Pediatric and Adolescent Gynecology
          Elsevier BV
          10833188
          August 2018
          August 2018
          : 31
          : 4
          : 376-381
          Article
          10.1016/j.jpag.2018.03.004
          5997553
          29551430
          © 2018

          Comments

          Comment on this article